A US subsidiary of French veterinary pharmaceutical company Ceva Sante Animale was hit with an antitrust suit in Kansas federal court claiming it monopolized the market for animal anti-anxiety drugs by cutting out its distributors, reported Bloomberg Law.
“This is the rare case where the would-be monopolist previewed for its leading competitor a plan to restrict access to products, seize control of the market, impose discriminatory pricing, acquire monopoly power, and raise prices,” the suit claims.
It accuses Ceva Animal Health, which makes up to 90% of the pheromone-based products, of breaching its supply contract with H&C Animal Health.
Ceva Animal Health was founded in 1999 and has since grown rapidly to become the sixth largest animal health group globally.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
European Commission Approves Nippon Steel’s $14.9 Billion Buyout of U.S. Steel
May 6, 2024 by
CPI
Banco Sabadell Rejects Rival BBVA Merger Proposal
May 6, 2024 by
CPI
Novo Nordisk Foundation’s Acquisition Faces Regulatory Hurdles
May 6, 2024 by
CPI
Microsoft’s MAI-1 to Compete with Google and OpenAI in AI Language Models
May 6, 2024 by
CPI
Qantas Settles ‘Ghost Flights’ Case With Australian Watchdog for $120 Million
May 6, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI